Skip to Content

Paul Geller

Robbins Geller Rudman & Dowd LLP

Paul Geller, managing partner of Robbins Geller Rudman & Dowd LLP’s Boca Raton, Florida office, is a founding partner of the Firm, a member of its Management Committee, and head of the Firm’s Consumer Practice Group.

Paul’s 29 years of litigation experience is broad, and he has handled cases in each of the Firm’s practice areas. Notably, before devoting his practice to the representation of consumers and investors, he defended companies in high-stakes class action and multi-district litigation, providing him with an invaluable perspective. Paul has tried bench and jury trials on both the plaintiffs’ and defendants’ sides and has argued before numerous state, federal, and appellate courts throughout the country.


  • Emory University School of Law, J.D., 1993, with Highest Distinction
    • Editor, Emory Law Journal
    • Order of the Coif Legal Honor Society
    • Awarded multiple American Jurisprudence Book Awards for earning the highest grade in class
  • University of Florida, B.S., 1990, Psychology
    • Member, University Honors Program

Notable Cases

  • Paul was recently selected to serve in a leadership position on behalf of governmental entities and other plaintiffs in the sprawling litigation concerning the nationwide prescription opioid epidemic.
  • Paul also a critical member of the team that negotiated over $26 billion in settlements against certain opioid distributors and manufacturers.
  • Paul was a member of the leadership team representing consumers in the massive Volkswagen “Clean Diesel” emissions case. The San Francisco legal newspaper The
  • Recorder labeled the group that was appointed in that case, which settled for more than $17 billion, a “class action dream team.”
  • Paul is currently serving as a Lead Counsel in In re EpiPen (Epinephrine Injection, USP) Mktg., Sales Pracs. & Antitrust Litig., a nationwide class action that alleges that pharmaceutical company Mylan N.V. and others engaged in anti-competitive and unfair business conduct in its sale and marketing of the EpiPen auto-injector device. The case was recently settled for $609 million.
  • A $650 million recovery in a cutting-edge class action in In re Facebook Biometric Info. Privacy Litig., concerning Facebook’s use of biometric identifiers through its “tag” feature. In addition to the monetary recovery, Facebook recently disabled the tag feature altogether, deleting user facial profiles and discontinuing the use of facial recognition software.